Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

Abstract

Key Points NK cell natural cytotoxicity and antibody-dependent cellular cytotoxicity of patients with systemic mastocytosis are normal. Trispecific killer engagers (161533 TriKE) target NK cells from normal donors and systemic mastocytosis patients to kill mast cells.